Skip to main content
Equibles

Kevin Sayer

CEO

Dexcom Inc (DXCM)

Chairman

Dexcom Inc (DXCM)

Board Member

Dexcom Inc (DXCM)

Equibles does not estimate personal net worth.

Get an email with a short summary when Dexcom Inc publishes a filing, an earnings call transcript or a press release.

Get DXCM alerts

About Kevin Sayer

Kevin Sayer is recorded as Chairman and Board Member at Dexcom Inc (DXCM) since January 1, 2007 and CEO at Dexcom Inc (DXCM). The newest filing on record that lists Kevin Sayer as Chairman at Dexcom Inc (DXCM) is dated April 15, 2026. The proxy statement of Dexcom Inc reports total compensation of $16,282,598 for Kevin Sayer in fiscal 2025, including a base salary of $1,213,515. Disclosed compensation is on record for 9 fiscal years. Kevin Sayer has spoken on 22 earnings calls across 1 company, most recently for Dexcom Inc on July 30, 2025. Dexcom Inc is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Dexcom Inc includes Jacob Leach (CEO, COO, CTO and Board Member), Jacob S. Leach (CEO, COO and Board Member), Kevin R. Sayer (Chairman and Board Member) and 7 others.

Kevin Sayer on recent calls

“Today, we reported second quarter organic revenue growth of 15% compared to the second quarter of 2024. We continue to see strong category growth, focused execution by our team, and a growing contribution from our recent access wins.”
Chairman, Dexcom Inc Q2 FY2025 Earnings Call ·
“Today, we reported first quarter organic revenue growth of 14% compared to the first quarter of 2024. This represented our second straight quarter of re-accelerating revenue growth as we've benefited from continued strong category demand, recent access wins, and focused execution by our team.”
Chairman, Dexcom Inc Q1 FY2025 Earnings Call ·
“Today we reported fourth quarter organic revenue growth of 8% compared to the fourth quarter of 2023. This brought our full year organic revenue growth to 12%, which was in line with our latest 2024 guidance.”
Chairman, Dexcom Inc Q4 FY2024 Earnings Call ·
“Before we dive in, I want to take this opportunity to share an important update. As many of you saw in today's press release, our Chief Commercial Officer, Teri Lawver, has expressed her plan to retire from DexCom.”
Chairman, Dexcom Inc Q3 FY2024 Earnings Call ·
“Before we begin discussing Q2 results, let me state that overall category demand remains strong, and awareness of the value of CGM across the metabolic health spectrum continues to accelerate.”
CEO, Dexcom Inc Q2 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Dexcom Inc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Dexcom Inc (DXCM) $1,213,515 $16,282,598
2024 Dexcom Inc (DXCM) $1,157,254 $15,828,797
2023 Dexcom Inc (DXCM) $1,092,822 $15,712,244
2022 Dexcom Inc (DXCM) $953,424 $15,435,652
2021 Dexcom Inc (DXCM) $900,000 $11,985,324
2020 Dexcom Inc (DXCM) $800,000 $13,804,156
2019 Dexcom Inc (DXCM) $691,150 $10,279,373
2018 Dexcom Inc (DXCM) $600,875 $9,554,123
2017 Dexcom Inc (DXCM) $546,250 $7,924,868

Recent activity

Show 10 earlier activities